Venous Leg Ulcers (Crural Ulcer) - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2019’, provides an overview of the Venous Leg Ulcers (Crural ulcer) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Venous Leg Ulcers (Crural ulcer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Venous Leg Ulcers (Crural ulcer) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Venous Leg Ulcers (Crural ulcer)

- The report reviews pipeline therapeutics for Venous Leg Ulcers (Crural ulcer) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Venous Leg Ulcers (Crural ulcer) therapeutics and enlists all their major and minor projects

- The report assesses Venous Leg Ulcers (Crural ulcer) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Venous Leg Ulcers (Crural ulcer)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Venous Leg Ulcers (Crural ulcer)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Venous Leg Ulcers (Crural ulcer) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

CardioVascular BioTherapeutics Inc

CytoTools AG

Daval International Ltd

FirstString Research Inc

GangaGen Inc

MallInckrodt Plc

MediWound Ltd

NovaLead Pharma Pvt Ltd

Promore Pharma AB

CardioVascular BioTherapeutics Inc

CytoTools AG

Daval International Ltd

FirstString Research Inc

GangaGen Inc

MallInckrodt Plc

MediWound Ltd

NovaLead Pharma Pvt Ltd

Promore Pharma AB

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Venous Leg Ulcers (Crural Ulcer) - Overview

Venous Leg Ulcers (Crural ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Venous Leg Ulcers (Crural Ulcer) - Overview

Venous Leg Ulcers (Crural Ulcer) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Venous Leg Ulcers (Crural Ulcer) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Venous Leg Ulcers (Crural Ulcer) - Companies Involved in Therapeutics Development

CardioVascular BioTherapeutics Inc

CytoTools AG

Daval International Ltd

FirstString Research Inc

GangaGen Inc

MallInckrodt Plc

MediWound Ltd

NovaLead Pharma Pvt Ltd

Promore Pharma AB

Venous Leg Ulcers (Crural Ulcer) - Drug Profiles

Aimspro - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AUP-16 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CVBT-141B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

diperoxochloric acid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EBC-1013 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EscharEx - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Granexin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LL-37 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NLP-328 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-128 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-42909 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sodium hypochlorite - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Venous Leg Ulcers (Crural Ulcer) - Dormant Projects

Venous Leg Ulcers (Crural Ulcer) - Discontinued Products

Venous Leg Ulcers (Crural Ulcer) - Product Development Milestones

Featured News & Press Releases

Oct 01, 2018: Promore Pharma has enrolled first patient in HEAL LL-37 in Poland

Sep 06, 2018: Promore Pharma has conducted Investigator Meeting for HEAL LL-37 in Poland

Aug 22, 2018: Promore Pharma receives approval for Phase IIb trial with LL-37 in Poland

Jul 03, 2018: Promore Pharma receives approval for Phase IIb trial with LL-37

Oct 31, 2017: Promore Pharma Signs Agreement with CRO PCG Clinical Services

Sep 21, 2017: Promore Pharma Signs Manufacturing Agreement with APL

Sep 12, 2017: Promore Pharma presents at the symposium for hard-to-heal wounds in connection with Nordic Life Science Days

Sep 01, 2017: MediWound Successfully Completes Second Cohort of EscharEx Phase 2 Study

Jun 20, 2017: FirstString's President and CEO, Dr. Gautam Ghatnekar, Presents at the 2017 BIO International Convention in San Diego, CA

Jan 18, 2017: FirstString Research Wins Prestigious Tibbetts Award

Apr 21, 2015: SCRA Technology Ventures Company Shares Phase 2 Results

Oct 10, 2013: Pergamum announces final data from Phase I/II study of LL-37 in patients with chronic leg ulcers

Apr 19, 2013: Pergamum Reaches Last-Patient-Last-Visit In Phase I/II Trial Of LL-37 For Treatment Of Venous Leg Ulcers

Sep 11, 2012: Pergamum Announces Dosing Of First Patient In Phase I/II trial Of LL-37 For Hard-to-heal Wounds

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Venous Leg Ulcers (Crural Ulcer), H1 2019

Number of Products under Development by Companies, H1 2019 ...

List of Tables

Number of Products under Development for Venous Leg Ulcers (Crural Ulcer), H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Venous Leg Ulcers (Crural Ulcer) - Pipeline by CardioVascular BioTherapeutics Inc, H1 2019

Venous Leg Ulcers (Crural Ulcer) - Pipeline by CytoTools AG, H1 2019

Venous Leg Ulcers (Crural Ulcer) - Pipeline by Daval International Ltd, H1 2019

Venous Leg Ulcers (Crural Ulcer) - Pipeline by FirstString Research Inc, H1 2019

Venous Leg Ulcers (Crural Ulcer) - Pipeline by GangaGen Inc, H1 2019

Venous Leg Ulcers (Crural Ulcer) - Pipeline by MallInckrodt Plc, H1 2019

Venous Leg Ulcers (Crural Ulcer) - Pipeline by MediWound Ltd, H1 2019

Venous Leg Ulcers (Crural Ulcer) - Pipeline by NovaLead Pharma Pvt Ltd, H1 2019

Venous Leg Ulcers (Crural Ulcer) - Pipeline by Promore Pharma AB, H1 2019

Venous Leg Ulcers (Crural Ulcer) - Dormant Projects, H1 2019

Venous Leg Ulcers (Crural Ulcer) - Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Venous Leg Ulcers (Crural Ulcer), H1 2019

Number of Products under Development by Companies, H1 2019 ...

List of Figures

Number of Products under Development for Venous Leg Ulcers (Crural Ulcer), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Top 10 Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports